Cited by 903Virus-based gene therapy researchRNA Interference and Gene DeliveryCAR-T cell therapy research

The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.

Gene therapy clinical trials worldwide to 2017: An update

Ginn, Samantha L., Amaya, Anais K., Alexander, Ian E., Edelstein, Michael, Abedi, Mohammad R.·2018·The Journal of Gene Medicine

Abstract

To date, almost 2600 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. Our database brings together global information on gene therapy clinical activity from trial databases, official agency sources, published literature, conference presentations and posters kindly provided to us by individual investigators or trial sponsors. This review presents our analysis of clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of our November 2017 update, we have entries on 2597 trials undertaken in 38 countries. We have analysed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and the genes that have been transferred. Details of the analyses presented, and our searchable database are available via The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. We also provide an overview of the progress being made in gene therapy clinical trials around the world, and discuss key trends since the previous review, namely the use of chimeric antigen receptor T cells for the treatment of cancer and advancements in genome editing technologies, which have the potential to transform the field moving forward.

Overview

Integrity signals

Registry

Crossref · 10.1002/jgm.3015

Cites

146 of 146 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 146 references

Research works printed but not linked: 6

  1. Aiuti A, 2009, Ten years of gene therapy for primary immune deficiencies. Hematology 2009 – the Education Program of the American Society of Hematology, Education Program, 2009, 682
  2. GeorgeLA RagniMV Samelson‐JonesBJ et al.Preliminary results from a phase 1/2 dose escalation trial of an investigational AAV‐mediated gene therapy for hemophilia A. American Society of Hematology 59th Annual Meeting and Exposition. Online Conference Proceedings; 9 December2017.https://ash.confex.com/ash/2017/webprogram/Paper108679.html[30 January 2018].
  3. Constable IJ, 2016, Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT‐1 for wet age‐related macular degeneration. E, Biol Med, 14, 168
  4. MonahanP WalshCE PowellJS et al.Update on a phase 1/2 open‐label trial of BAX335 an adeno‐associated virus 8 (AAV8) vector‐based gene therapy program for hemophilia B. Proceedings of the XXV International Society on Thrombosis and Haemostasis Conference.North Carolina USA:Carrboro;2015;13(Suppl 2): LB010):87.
  5. Abeona Therapeutics.Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO‐102 Gene Therapy For Patients with MPS IIIA: Clinical Trial Notification (CTN) Enables Initiation at 3rd Global Site and Accelerates Enrollment in the ABO‐102 MPS IIIA Gene Therapy Program. Abeona Therapeutics: Press Release 9 May2017.https://globenewswire.com/news-release/2017/05/09/980972/0/en/Abeona-Therapeutics-Receives-Regulatory-Approval-to-Initiate-Clinical-Trial-in-Australia-with-ABO-102-Gene-Therapy-For-Patients-with-MPS-IIIA.html[3 April 2018].
  6. Amgen.FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US. AMGEN website: Press Release 27 October2015.http://www.amgen.com/media/news‐releases/2015/10/fda‐approves‐imlygic‐talimogene‐laherparepvec‐as‐first‐oncolytic‐viral‐therapy‐in‐the‐us/[30 January 2018].

Cited by

Sorted by citations

Items 201–300 of 903

Metadata

Authors
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R.
Affiliations
  • The University of Sydney (AU)
  • Chatham House (GB)
  • Uppsala University Hospital (SE)
Corresponding author
Ginn, Samantha L.
Venue
The Journal of Gene Medicine
Publisher
Wiley
Published
2018-04-19
Volume
20
Issue
5
Pages
e3015-e3015
ISSN
  • 1099-498X (ISSN-L)
  • 1521-2254
OpenAlex
W2983048398
Cited by
903
References
146
Citations by year
2026: 31 · 2025: 68 · 2024: 86 · 2023: 77 · 2022: 124 · 2021: 141 · 2020: 151 · 2019: 148 · 2018: 36
FWCI
16.66
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Gene Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
gene therapy, clinical trials, clinical trial database, gene therapy vectors, disease indications, chimeric antigen receptor T cells, cancer immunotherapy, genome editing, clinical trial trends
MeSH terms
Clinical Trials as Topic, Humans, Neoplasms, Global Health, Genetic Therapy, Immunotherapy, Adoptive, Outcome Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review